We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Mitochondrial Breakdown Promotes Death of Hypoxic Cells

By LabMedica International staff writers
Posted on 30 Nov 2011
Combining and breaking down of mitochondria are linked to how cells respond to changes in their environment. More...
A recent study has identified a molecular pathway critical to this process.

Investigators at the Sanford-Burnham Medical Research Institute (La Jolla, CA; USA) exposed cardiomyocyte cultures to low oxygen concentrations (hypoxia) that were similar to conditions found in the heart muscle following a heart attack.

They reported in the November 18, 2011, issue of the journal Molecular Cell that hypoxia-induced fission of mitochondrial membranes, dependent on availability of the mitochondrial scaffolding protein AKAP121.

Mitochondrial fission, which caused the heart cells to die, was stimulated when the ubiquitin ligase Siah2 reduced availability of AKAP121. Siah2 gene is a member of the seven in absentia homolog (Siah) family of proteins. The enzyme is an E3 ligase and is involved in ubiquitination and proteasome-mediated degradation of specific proteins. The activity of this ubiquitin ligase has been implicated in regulating cellular response to hypoxia.

Suppressing the activity of Siah2 in hypoxic cells or in mice increased AKAP121 levels, which reduced mitochondrial fission and resulted in death of fewer heart cells. Under hypoxic conditions, Siah2-deficient mice fared better than their normal counterparts did.

“Our work reveals key aspects to controlling mitochondrial dynamics in response to low oxygen tension,” said senior author Dr. Ze'ev A. Ronai, associate director the cancer center at the Sanford-Burnham Medical Research Institute. “By manipulating mitochondrial dynamics, we can help cells adapt to ischemic conditions in a way that might translate into new treatment options for patients who have experienced a heart attack.”

Research efforts are now focused on the pursuit of chemical compounds to inhibit Siah2 that can be further developed into new therapies to prevent or reverse cardiac damage.

Related Links:

Sanford-Burnham Medical Research Institute








Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.